John Henneman

NewLink Genetics Corp (NASDAQ: NLNK) and licensing partner Merck & Co., Inc. (NYSE: MRK) appear to have made a major breakthrough in prevention of one of the deadliest diseases in the world. This week, The Lancet reported 100 percent efficacy in Merck's final-stage trial of an experimental...